For successful TB treatment the patient must take a combination of TB drugs. Now that drugs are available surgery is only occasionally used as treatment for TB. There are more than twenty drugs available for TB treatment. Which ones have to be taken depends on the circumstances of the patient.
If you are having TB treatment (sometimes known as antitubercular treatment or ATT), then this should always be supervised by an experienced doctor or other health person.
TB treatment, the TB drugs
A patient must take their drugs properly. But it is also the responsibility of the doctor to make sure that the patient has the correct drugs. The doctor must also explain to the patient how to take the drugs correctly. In many countries there are "alternative" medicines available. But the doctor must make sure that the patient knows that it is only officially recommended TB drugs that can cure TB.
To cure TB a patient needs to take several drugs. If only one drug is taken then it is very likely that the treatment won't work, or if it does work initially then the patient may later on become sick again. A patient is said to have a relapse if they improve whilst taking TB treatment but become ill again after they have finished their treatment.
If a patient is failing their treatment this means that they are either developing TB symptoms again, or their symptoms are not going away at all. If this happens then a doctor should be consulted about changing the drugs. It is not satisfactory to just add one drug to what the patient is already taking.
What causes TB?
TB is caused by bacteria which are in a person's body. TB drugs can kill all the TB bacteria in a person's body. This means that the person is then cured of TB.
But TB bacteria die very slowly, and so the drugs have to be taken for several months. Even when a patient starts to feel better they can still have bacteria alive in their body. So the person needs to keep taking the drugs until all the bacteria are dead.
All the drugs must be taken for the entire length of the TB treatment. If only one or two TB drugs are taken then only some of the bacteria may be killed. They may then become resistant to the TB drugs which then don't work. If the person becomes sick again then different TB drugs called second line drugs may be needed.
What drugs should a patient take
The drugs that a patient should take depends on whether the patient has ever had TB treatment before. If the patient has never had treatment before then it can be assumed that the bacteria in the patient's body will respond, and be sensitive to all the TB drugs. So the patient can then be given the following drugs:
- & Ethambutol.
These are the TB drugs that generally have the greatest activity against TB bacteria. They are called the "First line" drugs.
There are just two exceptions for patients being given these drugs. The first exception is if the local doctors know that there is a high level of resistance to the drug isoniazid in patients in the local area. The second exception is if the patient has been known to be in contact with a patient who is known to have drug resistant TB. In either of these situations the patient may need to receive different drugs.
FDCs are when several drugs are put together in one tablet or pill. This helps to ensure that all the drugs are taken.
Length of TB treatment for new patients
For new patients with presumed drug susceptible pulmonary TB, the World Health Organisation (WHO) recommends that they should have six months of treatment. This consists of a two month intensive phase followed by a four month continuation phase.
For the two month intensive TB treatment phase they should receive:
- plus rifampicin
- plus pyrazinamide
- plus ethambutol
- plus rifampicin
for the continuation treatment phase.
It is recommended that patients take the TB drugs every day for six months. Taking the drugs three times a week used to be considered satisfactory but is no longer recommended by the WHO. It is essential that all the recommended TB drugs are taken.
If only one or two drugs are taken, then the TB treatment probably won't work.
Reduction in the length of TB treatment
It is possible that the six month length of treatment could soon be reduced to four months.
A trial has shown that a four month treatment regimen using rifapentine is just as effective as a six month regimen. In a trial a four month regimen containing rifapentine and moxifloxacin worked just as well as the standard six month regimen.1
"Patient adherence to the taxing drug regimen has been a huge problem worldwide , and it is the main factor that has given rise to the very drug-resistant forms of TB that are much more toxic, expensive and time-consuming to treat"
Treatment for patients previously treated
If patients have been previously treated it is essential that they have a drug susceptibility test to find out if they have any drug resistance.
If the bacteria that they are infected with are not resistant to any of the first line drugs then the standard first line treatment can be repeated. If there is resistance then an MDR-TB regimen should be prescribed according to WHO's guidance for the treatment of drug resistant TB.
TB treatment failure
It is often suggested that TB treatment fails because a patient doesn’t take their TB drugs correctly. However there can be a number of different reasons for TB treatment failure.
It is certainly true that if a patient doesn’t take their TB drugs properly that this can lead to the development of drug resistant TB. However the patient may already have drug resistant TB. If they already have drug resistant TB, then the treatment that someone is provided with may result in treatment failure even if the treatment is taken correctly.
The three main causes of treatment failing, relate to the actions of doctors in prescribing incorrect regimes, the fact that there may be problems with the drugs being delivered (either when they are delivered or the quality), and that patients for a number of reasons may not have a sufficient intake of the drugs.2
Patients who experience only a short improvement whilst on treatment, or who never respond to treatment, are said to have failed their TB treatment. Treatment failure is also sometimes defined as the continued presence of positive sputum or culture (positive result to a culture test). It can also be that positive sputum or culture appears again during the course of a patient’s anti tuberculosis drug treatment (att).3
After three months of drug treatment for pulmonary TB caused by drug susceptible bacteria, 90-95% of patients will have negative sputum or culture and show clinical improvement. Normally it is considered that if a patient still has a positive culture after three months of treatment, the patient must be carefully evaluated to identify why their positive culture hasn’t changed to negative. Patients whose sputum culture remains positive after four months of drug treatment should be classified as treatment failures. If drug treatment failure occurs then a sample should be sent to a reference laboratory for drug susceptibility testing for both first and second line drugs.
Relapse & recurrence
A patient is said to relapse if they become and remain culture negative (or they become well) whilst on TB treatment. They then become culture positive (or become ill) again after finishing their TB treatment.
Recurrence of active TB is usually used to refer to the situation when a person’s first TB treatment appears to have been successful. There has then been a significant time interval before active TB develops again. This may either be because of reactivation of the person’s previously latent TB or because they have been reinfected.
If any of these situations occur it must be considered a real possibility that the person has drug resistant TB. Their new TB treatment programme must be decided taking this into account.
To decide what treatment patients need, the World Health Organisation (WHO) used to put patients into TB treatment categories. But with the increasing availability of drug susceptibility testing (DST), treatment categories were abolished, and DST is now used instead to decide on the treatment that patients need.
TB treatment monitoring
All patients receiving TB treatment should be monitored during their treatment to assess their response to the drug treatment. Regular monitoring helps to ensure that patients complete their treatment. It can also help to identify and manage adverse drug reactions. Patients also need to have their weight checked every month, and if the patient’s weight changes the drug dosages may need to be adjusted.4 The patient also needs to have an adequate intake of food. There is more about food & TB.
When patients have pulmonary TB the patients response to TB treatment should be monitored using sputum smear microscopy. The recommendation from WHO is that for smear positive TB patients treated with first line drugs, the patients should have smear microscopy performed at the end of the two month intensive phase of treatment.
Positive sputum smear
If the patient has a positive sputum smear at the end of the intensive phase, then there should be a patient assessment carried out. This is because the positive smear could indicate a number of different situations. An example is that the patient might have drug resistant TB, and a change in the TB drugs they are taking might be needed. Alternatively, patient adherence might have been poor, and they might not have been taking their drugs correctly. So the assessment might result in changes needing to be made to the patient’s treatment, or to their support and supervision. Different action may need to be taken in a variety of other circumstances, such as the patient having received treatment before.
This page was last updated in July 2022
Author: Annabel Kanabus
Web site linking
If you have a web site and you have found this page useful, then please link to us at https://tbfacts.org/tb-treatment/
- Novel tuberculosis regimen shortens treatment course for patients, 2021, https://www.timesnownews.com/health/article/novel-tuberculosis-regimen-shortens-treatment-course-for-patients/766554
- Based on Lambregts-van Weezenbeck, C. S. “Control of drug-resistant tuberculosis” Tubercle and Lung Disease, (1995) 76, 455
- “Monitoring of relapse, treatment failure and drug resistance”, British HIV Association www.bhiva.org/
- “Guidelines for treatment of Tuberculosis”, WHO, Geneva, 2010, 85
- “Early tuberculosis treatment monitoring by Xpert MTB/RIF”, European Respiratory Journal, May 1 2012 //erj.ersjournals.com/content/39/5/1269.extract#